Higher Gradient Whole-Body MRI Scanner Gets FDA Nod
At an amplitude of 200 mT/m and a slew rate of 200 T/m/s, the gradients for the FDA-cleared MAGNETOM Cima.X are reportedly the strongest for currently available whole-body MRI scanners.
Offering a robust gradient system and a variety of workflow enhancements, the MAGNETOM Cima.X 3T whole-body magnetic resonance imaging (MRI) scanner has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Siemens Healthineers, the manufacturer of the MAGNETOM Cima.X system, said the device features Gemini Gradients that have an amplitude of 200 millitesla per meter (mT/m) and a slew rate of 200 telsa per meter per second (T/m/s).
For imaging of patients with neurodegenerative diseases, the industry-leading gradient strength enhances the visibility of microstructures in the brain, according to Siemens Healthineers. The company noted that the MAGNETOM Cima.X system also features the artificial intelligence (AI)-powered Deep Resolve reconstruction technology, which can accelerate MRI brain scans by 70 percent.
The newly FDA-cleared, whole-body MAGNETOM Cima.X MRI system offers enhanced gradient strength that may facilitate improved visualization of brain microstructures as well as artificial intelligence (AI)-powered reconstruction technology that can accelerate MRI brain scans by 70 percent, according to Siemens Healthineers, the manufacturer of the system.
Another benefit of the whole-body MRI modality, according to Siemens Healthineers, is the capability to provide time-stamped physiological data through the system’s Physiologging feature, which enables clinicians to ascertain whether respiratory activity is compromising brain activity.
“With the FDA clearance of the MAGNETOM Cima.X, Siemens Healthineers proudly offers the scientific and medical communities a whole-body 3T MR scanner that can deliver penetrating new insights into oncologic, cardiac, and neurodegenerative disease,” noted Katie Grant, the vice president of magnetic resonance at Siemens Healthineers North America.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
Can a Six-Minute MRI Facilitate Detection of Multiple Sclerosis?
May 23rd 2025Recognition of the central vein sign with a six-minute MRI demonstrated comparable sensitivity for multiple sclerosis (MS) detection in comparison to oligoclonal band (OCB) assessment, which requires lumbar puncture, according to newly published research.
